Chemosensitivity and Endocrine Sensitivity Predicted by MammaPrint and BluePrint in the Prospective Neoadjuvant Breast Registry Symphony Trial

Authors

Mark A. Gittleman MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

12-2013

Published In/Presented At

Gittleman, M. (2013, December 10-14). Chemosensitivity and endocrine sensitivity predicted by mammprint and blueprint in the prospective neoadjuvant breast registry symphony trial. Poster presented at: The San Antonio Breast Cancer Symposium, San Antonio, TX.

Disciplines

Medical Specialties | Medicine and Health Sciences | Other Medical Specialties | Surgery

Department(s)

Department of Surgery

Document Type

Poster